WallStreetZenWallStreetZen

NYSEMKT: SER
Serina Therapeutics Inc Stock

$13.46-1.41 (-9.48%)
Updated Mar 28, 2024
SER Price
$13.46
Fair Value Price
N/A
Market Cap
$33.66M
52 Week Low
$10.90
52 Week High
$35.17
P/E
-0.98x
P/B
6.15x
P/S
102.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$142.00k
Earnings
-$14.80M
Gross Margin
71.8%
Operating Margin
-6,973.94%
Profit Margin
-10,424.6%
Debt to Equity
1.21
Operating Cash Flow
-$8M
Beta
0.96
Next Earnings
Mar 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SER Overview

AgeX Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Alameda, California and currently employs 12 full-time employees. The firm is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SER scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SER is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SER is good value based on its book value relative to its share price (6.15x), compared to the US Biotechnology industry average (6.21x)
P/B vs Industry Valuation
SER is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SER due diligence checks available for Premium users.

Be the first to know about important SER news, forecast changes, insider trades & much more!

SER News

Valuation

SER price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.98x
Industry
14.26x
Market
44.51x

SER price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.15x
Industry
6.21x
SER is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SER's financial health

Profit margin

Revenue
$56.0k
Net Income
-$3.5M
Profit Margin
-6,171.4%
SER's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SER's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$12.0M
Liabilities
$6.6M
Debt to equity
1.21
SER's short-term liabilities ($5.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SER's short-term assets ($754.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SER's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SER's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.1M
Investing
$0.0
Financing
$2.0M
SER's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SER vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SER$33.66M-9.49%-0.98x6.15x
PLUR$33.43M-8.41%-1.39x7.60x
SLS$32.38M-1.94%-0.66x-8.46x
SPRB$32.34M+6.22%-0.63x0.42x
ACST$32.19M+0.74%-0.67x0.50x

Serina Therapeutics Stock FAQ

What is Serina Therapeutics's quote symbol?

(NYSEMKT: SER) Serina Therapeutics trades on the NYSEMKT under the ticker symbol SER. Serina Therapeutics stock quotes can also be displayed as NYSEMKT: SER.

If you're new to stock investing, here's how to buy Serina Therapeutics stock.

What is the 52 week high and low for Serina Therapeutics (NYSEMKT: SER)?

(NYSEMKT: SER) Serina Therapeutics's 52-week high was $35.17, and its 52-week low was $10.90. It is currently -61.73% from its 52-week high and 23.45% from its 52-week low.

How much is Serina Therapeutics stock worth today?

(NYSEMKT: SER) Serina Therapeutics currently has 2,500,664 outstanding shares. With Serina Therapeutics stock trading at $13.46 per share, the total value of Serina Therapeutics stock (market capitalization) is $33.66M.

Serina Therapeutics stock was originally listed at a price of $95.31 in Nov 29, 2018. If you had invested in Serina Therapeutics stock at $95.31, your return over the last 5 years would have been -85.88%, for an annualized return of -32.39% (not including any dividends or dividend reinvestments).

How much is Serina Therapeutics's stock price per share?

(NYSEMKT: SER) Serina Therapeutics stock price per share is $13.46 today (as of Mar 28, 2024).

What is Serina Therapeutics's Market Cap?

(NYSEMKT: SER) Serina Therapeutics's market cap is $33.66M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Serina Therapeutics's market cap is calculated by multiplying SER's current stock price of $13.46 by SER's total outstanding shares of 2,500,664.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.